Overview: FVIII FIX Mutation TestIntroduction: The FVIII FIX Mutation Test detects mutations in factor VIII/IX genes to diagnose hemophilia, causing excessive bleeding. Aligned with 2023 ASH guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected hemophilia A or B.
Other Names: Factor VIII/IX Mutation Assay, Hemophilia Genetic Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Hemophilia genetic testing began in the 1980s with factor gene discoveries. PCR-based mutation detection emerged in the 1990s, and by the 2000s, expanded panels improved accuracy.
Purpose: Diagnoses hemophilia A or B, guides treatment, and monitors factor VIII/IX mutations in patients with excessive bleeding.
Test Parameters: 1. Factor VIII/IX Mutation
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like excessive bleeding, and list family history of hemophilia.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document excessive bleeding or family history of hemophilia. Include current medications or prior genetic testing results.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for genetic counseling or therapy.
Procedural Considerations: Uses PCR to detect factor VIII/IX gene mutations. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Contamination or low DNA yield can affect results. Rare mutations may require additional testing.
Clinical Significance: Positive mutation results confirm hemophilia A or B, prompting factor replacement therapy or genetic counseling. Negative results may require further testing.
Specialist Consultation: Consult a hematologist or geneticist for result interpretation.
Additional Supporting Tests: Factor VIII/IX functional tests, aPTT, or bleeding time to confirm hemophilia.
Test Limitations: False negatives may occur with rare mutations. Results require clinical correlation.
References: ASH Hemophilia Guidelines, 2023; Blood, Peyvandi F, 2022.
